Developer · 3692.HK · China
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Operating company of Hansoh Pharmaceutical Group Company Limited (HKEX: 3692), a Chinese innovative-drug company whose focus areas include oncology, metabolism, immunology, central nervous system (CNS) and anti-infectives. Registered sponsor of all ClinicalTrials.gov studies of obuprazine (HS-10380) in schizophrenia.
Pipeline (1)
- SchizophreniaPhase 2Active
Catalysts · 0 upcoming · 1 reported
Recently reported
- 2026-10-10met
Obuprazine (HS-10380)forSchizophreniaFull results
Phase 2b of obuprazine (HS-10380) in acute schizophrenia met its primary endpoint: all three dose ranges beat placebo on PANSS total change at Day 42 (LSMD -16.7, -13.2, -14.7; aripiprazole -12.1); presented at ECNP 2026.
Recent activity
- Oct 10, 2026ReadoutObuprazine (HS-10380)·SchizophreniametPhase 2b of obuprazine (HS-10380) in acute schizophrenia met its primary endpoint: all three dose ranges beat placebo on PANSS total change at Day 42 (LSMD -16.7, -13.2, -14.7; aripiprazole -12.1); presented at ECNP 2026.source ↗
- May 23, 2024Phase changeObuprazine (HS-10380)·SchizophreniaPhase 2Phase 2b in hospitalized adults with acute schizophrenia (NCT07550387, HS-10380-202) started (actual date per ClinicalTrials.gov); primary completion 2026-01-02, study completion 2026-01-19. Registered retrospectively (first posted 2026-04-24).source ↗
- Jul 30, 2023Phase changeObuprazine (HS-10380)·SchizophreniaPhase 1/2Phase 1b/2 in Chinese adults with schizophrenia (NCT05964790, HS-10380-201) registered with an ESTIMATED start of 2023-07-30; the record was never updated (status UNKNOWN), so the date is approximate.source ↗
- Aug 1, 2022Phase changeObuprazine (HS-10380)·SchizophreniaPhase 1First-in-human SAD/MAD study in Chinese healthy adults (NCT05480592, HS-10380-101) started per ClinicalTrials.gov (registered under schizophrenia; record status since UNKNOWN).source ↗
Trials recruiting · 1 recruiting of 13 sponsored
- Phase 3HS-10506, Placebo
A Study of HS-10506 in Chinese Patients With Insomnia Disorder
Competitive landscape
Other companies developing against Jiangsu Hansoh Pharmaceutical Co., Ltd.'s targets or indications.
- Alkermes plc1 compoundSchizophrenia
- Alto Neuroscience, Inc.1 compoundSchizophrenia
- Avanir Pharmaceuticals1 compoundSchizophrenia
- BioXcel Therapeutics, Inc.1 compoundSchizophrenia
- Boehringer Ingelheim2 compoundsSchizophrenia
- Celon Pharma S.A.1 compoundSchizophrenia
- Cerevel Therapeutics1 compoundSchizophrenia
- Eli Lilly and Company2 compoundsSchizophrenia
- F. Hoffmann-La Roche Ltd1 compoundSchizophrenia
- Intra-Cellular Therapies, Inc.1 compoundSchizophrenia
- Karuna Therapeutics1 compoundSchizophrenia
- LB Pharmaceuticals Inc.1 compoundSchizophrenia